VR Adviser’s Rallybio RLYB Stock Holding History

VR Adviser’s Portfolio RLYB Stock Details RLYB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-33,567	Closed	-$905K	–	40
2023 Q3	$905K	Hold	33,567	–	–	0.1%	36
2023 Q2	$1.52M	Hold	33,567	–	–	0.24%	28
2023 Q1	$1.53M	Hold	33,567	–	–	0.3%	24
2022 Q4	$1.76M	Hold	33,567	–	–	0.3%	28
2022 Q3	$3.89M	Hold	33,567	–	–	0.6%	29
2022 Q2	$2.03M	Buy	+33,567	New	+$2.52M	0.4%	26

Other funds holding RLYB

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

CPX

Canaan Partners XI Menlo Park, California $76.1M AUM 638.59% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

VR Adviser's RLYB Position: Q4 2023 in Review

VR Adviser sold out of Rallybio (RLYB) in Q4 2023, closing a stake of 33,567 shares — an estimated $905K sold.

VR Adviser first reported a position in RLYB in Q2 2022 and held it in 6 quarters. The position peaked at $3.89M in Q3 2022. 54 funds tracked by Wall St. Rank hold RLYB as of Q4 2023.

VR Adviser reported no remaining Rallybio position as of Q4 2023 after selling out during the quarter.
VR Adviser sold 33,567 Rallybio shares in Q4 2023, an estimated $905K.
VR Adviser first reported a position in Rallybio in Q2 2022 and held it in 6 quarters.
VR Adviser's Rallybio position peaked at $3.89M in Q3 2022.
54 funds tracked by Wall St. Rank held Rallybio as of Q4 2023.

Based on VR Adviser's 13F filing for Q4 2023, filed 14 Feb 2024.